TRINTELLIX

This brand name is authorized in United States. It is also authorized in Canada, Japan.

Active ingredients

The drug TRINTELLIX contains one active pharmaceutical ingredient (API):

1	Vortioxetine UNII TKS641KOAY - VORTIOXETINE HYDROBROMIDE
	Vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, leading to modulation of neurotransmission in several systems, including predominantly the serotonin but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems. This multimodal activity is considered responsible for the antidepressant and anxiolytic-like effects and the improvement of cognitive function, learning and memory observed with vortioxetine in animal studies.
	Read more about Vortioxetine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRINTELLIX Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AX26		N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX26

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02432919, 02432927, 02432943
JP	医薬品医療機器総合機構	1179060F1028, 1179060F2024
US	FDA, National Drug Code	55154-0256, 55154-0257, 64764-720, 64764-730, 64764-750, 70518-2642